PharmaMar (BME: PHM) revenue
PharmaMar reported revenue of €221.4m for fiscal 2025, 26.6% more than in fiscal 2024 (€174.9m). Since fiscal 2019 its revenue has grown by 158.0%, an average growth of 17.1% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | €221.4m | +26.6% | €60.7m | 27.4% |
| 2024 | €174.9m | +10.6% | €6.5m | 3.7% |
| 2023 | €158.2m | −19.5% | −€3.8m | −2.4% |
| 2022 | €196.3m | −14.6% | €44.1m | 22.4% |
| 2021 | €229.8m | −14.9% | €92.4m | 40.2% |
| 2020 | €270.0m | +214.6% | €155.9m | 57.8% |
| 2019 | €85.8m | — | −€17.5m | −20.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the revenue of PharmaMar
- How much revenue did PharmaMar make in fiscal 2025?
- PharmaMar reported revenue of €221.4m for fiscal 2025, compared with €174.9m in fiscal 2024.
- How much has the revenue of PharmaMar grown?
- Between fiscal 2019 and fiscal 2025 it went from €85.8m to €221.4m: 158.0% more, an average growth of 17.1% a year.
- What was the best year for revenue at PharmaMar?
- Of its last 7 fiscal years, fiscal 2020, with €270.0m.
- Where do the figures for PharmaMar come from?
- From the report PharmaMar files every year in the European single electronic format (ESEF), the same one the CNMV, the Spanish regulator, receives. Each fiscal year links to its filing.
Where each figure comes from
From the annual report PharmaMar files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on PharmaMar: the PharmaMar page · annual accounts · net income · dividends paid.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.